Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
Gruppen-Retreat-Psilocybin-Therapie für Menschen mit metastasiertem Krebs und Symptomen von Angst und Depression: Sicherheits- und Wirksamkeitsdaten einer Phase-1/2-Studie
Psychedelic Medicine · 01.09.2026 · 4 (3) · 209-221
DOI: 10.1177/28314425251413856 ↗Auf einen Blick
Bei 52 Personen mit metastasiertem Krebs war eine Gruppen-Psilocybin-Therapie in einem 3-tägigen Retreat ohne unbeaufsichtigte Distress-Episoden durchführbar. Die HADS-Symptomwerte sanken bis Tag +28.
Fragestellung
Sicherheit und explorative Wirksamkeit einer Gruppenform der Psilocybin-Therapie bei metastasiertem Krebs mit Angst- und Depressionssymptomen.
Methode
Phase-1/2-Studie mit 8 Retreats; 2 virtuelle Vorbereitungssitzungen, 3-tägiges Retreat und 2 virtuelle Integrationssitzungen; Psilocybin 25 mg oral.
Ergebnisse
55 eingeschlossen, 3 vor dem Retreat ausgeschieden, 52 analysiert. Kein Fall von unbeaufsichtigtem Participant distress mit Bedarf an Backup-Facilitator. HADS von 17,5 an Tag −14 auf 10,2 an Tag +28; Differenz 7,3 (p < 0,0001).
Schlussfolgerung der Autor:innen
Die Group Retreat Psilocybin Therapy war sicher und gut verträglich; die explorativen Daten sind vielversprechend. Eine Gruppe mit 8 Teilnehmenden und 4 Kern-Facilitators kann für weitere Studien sicher sein.
Kernaussagen
- Kein Fall von unbeaufsichtigtem Distress mit Bedarf an Backup-Facilitator
- HADS sank von 17,5 auf 10,2 bis Tag +28
- 8 Teilnehmende und 4 Kern-Facilitators waren im Retreat machbar
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Psychedelic Medicine, online erschienen am 18.01.2026. Verfasst von Anthony L. Back und 12 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Steven and Alexandra Cohen Foundation.
Themen: Depression
Abstract (Originalsprache)
Background
Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression.
Method
Eligibility criteria included metastatic cancer, moderate-to-severe symptoms of anxiety or depression without a pre-cancer mental health diagnosis, performance status adequate to attend a 3-day retreat that required self-care, and tapering of antidepressants. Exclusion criteria included enrollment in hospice. The design of the intervention included: two virtual preparatory sessions; a 3-day in-person retreat in a rustic setting that included the third prep session, the psilocybin session, and the first integration session; and two additional virtual integration sessions. Psilocybin was administered in oral capsules at 25 mg. A retreat team of four core facilitators and two backup facilitators conducted a series of eight retreats. The first retreat had five participants. For subsequent retreats, we used the primary safety outcome from each cohort, other safety outcomes, and qualitative feedback to make decisions to increase, decrease, or hold steady the participant number. The primary safety outcome was “unattended episodes of participant distress” during the psilocybin session requiring a backup facilitator. The primary exploratory efficacy outcome was reduction in anxiety and depression symptoms measured using the Hospital Anxiety and Depression Scale (HADS).
Results
We enrolled 55 participants, of whom 3 withdrew prior to the retreat, leaving a total of 52. Their mean age was 53, and mean duration of living with cancer was 36 months, mean (range 5, 176); anticancer therapy was ongoing for 46 (88%); antidepressants were tapered for 18 (35%). The first retreat cohort had five participants, and the final retreat cohort had eight. For the primary safety outcome, there was not a single episode of unattended participant distress requiring a backup facilitator. The mean baseline at Day −14 (D −14) HADS total score was 17.5 (range 6–28); at D +28, the mean HADS total score was 10.2 (1–30), so the mean decrease in HADS from D −14 to D +28 was 7.3. ( p < 0.0001).
Conclusion
The Group Retreat Psilocybin Therapy was safe and well tolerated, and exploratory measures show efficacy that is promising. A group configuration of eight participants with four core facilitators can be safe for future studies with participants with serious medical illness.
Förderung
- Steven and Alexandra Cohen Foundation
Zitieren
APA
Back, A. L., McGregor, B. A., Thorn, L. L., Baker, K., Gooley, T., Kaelen, M., Harvey, K., Guy, J. M., Myers, S., Perez, J., Thompson, P., Billingsley, L., & Sesnon, C. (2026). Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study. Psychedelic Medicine, 4(3), 209-221. https://doi.org/10.1177/28314425251413856
Vancouver
Back AL, McGregor BA, Thorn LL, Baker K, Gooley T, Kaelen M, et al. Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study. Psychedelic Medicine. 2026;4(3):209-221. doi:10.1177/28314425251413856
BibTeX
@article{Back2026,
author = {Back, Anthony L. and McGregor, Bonnie A. and Thorn, Leslie L. and Baker, Kelsey and Gooley, Ted and Kaelen, Mendel and Harvey, Kalin and Guy, John M. and Myers, Susanna and Perez, Juliana and Thompson, Peter and Billingsley, Lindsay and Sesnon, Cheryl},
title = {Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study},
journal = {Psychedelic Medicine},
year = {2026},
volume = {4},
number = {3},
pages = {209--221},
doi = {10.1177/28314425251413856}
}
EUVIMED